| |
|
|
|
Enlivex Therapeutics Ltd  
|
|
11 0.08 (0.01%) |
09-16 16:00 |
|
Open: |
10.84 |
Pre close: |
10.92 |
Target:
|
14.27 
|
|
High: |
11.16 |
Low: |
10.61 |
Resistance:
|
12.22
13.95
|
|
Volume: |
41,307 |
Market Cap: |
201M |
Support:
|
9.41
7.83
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
11.16
 |
MACD |
MACD(12,26):
|
0.35 |
|
MA(20): |
11.36 |
Signal(12,26,9): |
0.56 |
|
MA(100): |
9.63 |
Stochastic Oscillator |
%K(14,3):
|
18.67 |
|
MA(250): |
10.85 |
%D(3): |
27.77 |
|
Average Volume(K) |
3-Month: |
3067626
|
52-Week |
High:
|
29.40 |
|
10-Days: |
319330 |
Low: |
4.73 |
|
RSI |
RSI(14):
|
51.11 |
Change(%): |
108.3 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.990 |
Return on Equity (ttm) |
-23.8 |
Shares Out. (M) |
18.31 |
|
EPS Est. Current Year |
0.000 |
Return on Assets (ttm) |
-12.7 |
Shares Float (M) |
13.74 |
|
EPS Est. Next Year |
0.000 |
PEG Ratio |
0.00 |
% Held by Insiders |
21.93 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
13.58 |
|
Forward EPS |
-1.400 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
142 |
|
Book Value (p.s.) |
4.950 |
EBITDA (p.s.) |
-0.702 |
P/E |
-11.11 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
2.22 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-14.86 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-6.59 |
P/CF |
-13.55 |
|
|
|
|
|
|
